The NK cancer drug provider has filed to go public in an offering which would enable GC and its GC Labcell subsidiary to exit.

Artiva Biotherapeutics, a US-based immunotherapy developer backed by pharmaceutical group GC, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2019, Artiva is working on cell-based cancer therapies. Its lead drug candidate, AB-101, helps the body produce natural killer (NK) cells that destroy cancer and tumour cells. The proceeds…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.